top of page

The Need for Early Detection of Chemotherapy Resistance in Ovarian Cancer

Srushika Bhavanolam
21/11/26

Background: Ovarian cancer has a high mortality rate due to late stage detection and the development of chemotherapy resistance in ovarian cancer cells. Platinum based chemotherapy is initially very effective in treating ovarian cancer, but recurrence and treatment resistance are major problems that arise. Aim: This paper shows the importance of detecting ovarian cancer early to mitigate chemotherapy resistance with an emphasis on liquid biopsy, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and molecular biomarkers.

Method: By reviewing several papers on PubMed, NCBI, and clinical trial registries with keywords such as ovarian cancer, liquid biopsy, and chemotherapy resistance, information was gathered. Studies relevant to diagnostic tools, biomarkers, and chemotherapy mechanisms were analyzed and clinical trials were compared to evaluate the current applications of ctDNA and other liquid biopsy approaches.

Results: Liquid biopsies are minimally invasive and highly informative for not only early detection, but also monitoring chemotherapy resistance. Biomarkers involving BRCA1/2, TP53 are associated with resistance pathways based on research. Ongoing clinical trials are evaluating whether ctDNA can detect recurrence, treatment response, and residual disease earlier than conventional monitoring but these studies by themselves do not establish clinical benefit.

Conclusion: Liquid biopsy may complement conventional assessment because it could provide molecular information during and also after treatment. Further validation is needed to establish when these tests will be able to reliably identify clinically actionable resistance and be able to improve patient management.

bottom of page